Finance

Lists
Q3 2026 earnings • in 4 days
See details
ALM:BME
Almirall SA
€11.12
+2.02%
(+0.22) 1D
Nov 4, 5:36:00 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALM...
Open
€10.98
High
€11.18
Low
€10.78
Mkt. cap
2.44B
Avg. vol.
108.55K
Volume
136.79K
Dividend
1.68%
Quarterly dividend
€0.05
Ex-dividend date
May 30, 2017
P/E ratio
41.21
52-wk high
€13.98
52-wk low
€9.81
EPS
€0.27
Shares outstanding
217.78M
No. of employees
2K
Open
€10.98
High
€11.18
Low
€10.78
Mkt. cap
2.44B
Avg. vol.
108.55K
Volume
136.79K
Dividend
1.68%
Quarterly dividend
€0.05
Ex-dividend date
May 30, 2017
P/E ratio
41.21
52-wk high
€13.98
52-wk low
€9.81
EPS
€0.27
Shares outstanding
217.78M
No. of employees
2K
News stories
From web sources and news partners
Profile
Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944. In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology. With approximately 1,904 employees, it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA. Wikipedia
About Almirall SA
CEOCarlos Gallardo Piqué | Gianfranco Nazzi
Employees2.1K
Founded1944
Headquarters-
SectorPharmaceutical industry
Industry-
Websitealmirall.com
Next call in 4 days
Mon, Nov 9, 3:00 AM
Fiscal period
Q3 2026
- / €0.08
Revenue / Est. (EUR)
- / 293.94M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
262.23M
288.93M
292.40M
313.22M
Cost of goods sold
157.74M
-27.67M
104.30M
31.26M
Cost of revenue
157.74M
-27.67M
104.30M
31.26M
Research and development expenses
102.40M
-102.40M
34.80M
-34.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
234.95M
-102.92M
121.60M
14.88M
Operating expense
81.32M
310.92M
158.10M
240.19M
Total operating expenses
239.05M
283.25M
262.40M
271.44M
Operating income
23.18M
5.69M
30.00M
41.78M
Other non operating income
2.16M
3.36M
-1.70M
-2.27M
EBT including unusual items
20.97M
9.35M
23.40M
37.45M
EBT excluding unusual items
23.37M
5.78M
24.50M
36.46M
Income tax expense
8.45M
2.29M
8.10M
13.20M
Effective tax rate
40.30%
24.54%
34.62%
35.24%
Other operating expenses
-179.66M
365.05M
1.70M
184.83M
Net income
12.52M
7.05M
15.30M
24.25M
Net profit margin
4.77%
2.44%
5.23%
7.74%
Earnings per share
-
-
-
-
Interest and investment income
1.37M
1.35M
1.00M
1.54M
Interest expense
-3.89M
-5.05M
-4.50M
-4.62M
Net interest expenses
-2.52M
-3.70M
-3.50M
-3.08M
Depreciation and amortization charges
-76.38M
151.18M
-
75.28M
EBITDA
69.66M
23.70M
67.50M
69.12M
Gain or loss from assets sale
-
199.00K
-
114.00K
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps